Attachment C. National HIV Prevention Program Monitoring and Evaluations (NHM&E) (OMB 0920-0696, Exp. 2/2018)

Variables No Longer Required (N=109)

|  |  |  |
| --- | --- | --- |
| Variable  Number | Variable Name | Variable Definition |
| CDC03 | CDC Variable 3 | This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD). |
| CDC04 | CDC Variable 4 | This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD). |
| CDC05 | CDC Variable 5 | This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD). |
|  |  |  |
| H01 | Intervention ID | An alpha-numeric identification code used to uniquely identify an intervention. |
| H01a | Intervention Name | The unique name of the intervention as defined by the agency. |
| H01b | Program Evidence Base | The name of a Program Evidence Base. |
| H01c | Specify Other Program Evidence Base | A name of a Program Evidence Base if 3.01 - Study / Special Study (specify) or 3.02-Other (specify) was selected in H01b. |
| H02 | Number of Planned Sessions | The total number of sessions planned for an intervention. The number of planned sessions can differ depending on the needs of individual clients (e.g., CRCS). |
| H05 | Number of Completed Sessions | The number of sessions that were completed by the client for a particular intervention. |
| H07 | Date of enrollment | The calendar month, day, and year on which the client enrolls in the intervention. |
| H08 | Program ID | A unique alpha-numeric identification number used to identify a program. |
| H08a | Program Name | The unique name of the program as defined by the agency. |
|  |  |  |
| ME100a | Program Delivery Year | The year which the HIV prevention program was delivered or implemented, and for which aggregate level data are being reported. |
| ME100b | Program Delivery Period | The 6-month period during which the HIV prevention program was delivered or implemented, and for which aggregate level data are being reported. |
| ME101 | Number of HIV-diagnosed clients linked to HIV medical care | The number of HIV-diagnosed clients who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101a | Number of HIV-diagnosed MSM/IDU linked to HIV medical care | The number of HIV-diagnosed MSM/IDU who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101b | Number of HIV-diagnosed MSM linked to HIV medical care | The number of HIV-diagnosed MSM who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101c | Number of HIV-diagnosed IDU linked to HIV medical care | The number of HIV-diagnosed IDU who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101d | Number of HIV-diagnosed heterosexuals linked to HIV medical care | The number of HIV-diagnosed heterosexuals who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101e | Number of HIV-diagnosed clients with other/unknown behavioral risk factors linked to HIV medical care | The number of HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101f | Number of HIV-diagnosed African Americans linked to HIV medical care | The number of HIV-diagnosed non-Hispanic blacks or African Americans who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101g | Number of HIV-diagnosed Hispanics linked to HIV medical care | The number of HIV-diagnosed Hispanics/Latinos of any race who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME101h | Number of HIV-diagnosed clients of other race/ethnicity linked to HIV medical care | The number of HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic/Latino, or unknown who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis. |
| ME102 | Number of HIV-diagnosed clients linked to treatment adherence services | The number of HIV-diagnosed clients who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102a | Number of HIV-diagnosed MSM/IDU linked to treatment adherence services | The number of HIV-diagnosed MSM/IDU who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102b | Number of HIV-diagnosed MSM linked to treatment adherence services | The number of HIV-diagnosed MSM who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102c | Number of HIV-diagnosed IDU linked to treatment adherence services | The number of HIV-diagnosed IDU who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102d | Number of HIV-diagnosed heterosexuals linked to treatment adherence services | The number of HIV-diagnosed heterosexuals who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102e | Number of HIV-diagnosed clients with other/unknown behavioral risk factors linked to treatment adherence services | The number of HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102f | Number of HIV-diagnosed African Americans linked to treatment adherence services | The number of HIV-diagnosed non-Hispanic blacks or African Americans who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102g | Number of HIV-diagnosed Hispanics linked to treatment adherence services | The number of HIV-diagnosed Hispanics/Latinos of any race who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME102h | Number of HIV-diagnosed clients of another race/ethnicity linked to treatment adherence services | The number of HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic/Latino, or unknown who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers. |
| ME103 | Number of out-of-care HIV-diagnosed clients re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed clients who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103a | Numbers of out-of-care HIV-diagnosed MSM/IDU re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed MSM/IDU who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103b | Numbers of out-of-care HIV-diagnosed MSM re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed MSM who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103c | Numbers of out-of-care HIV-diagnosed IDU re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed IDU who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103d | Numbers of out-of-care HIV-diagnosed heterosexuals re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed heterosexuals who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103e | Number of out-of-care HIV-diagnosed clients with other/unknown behavioral risk factors re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks, who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103f | Numbers of out-of-care HIV-diagnosed African Americans re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed non-Hispanic blacks or African Americans who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103g | Numbers of out-of-care HIV-diagnosed Hispanics re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed Hispanics/Latinos of any race who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME103h | Number of out-of-care HIV-diagnosed clients of another race/ethnicity re-engaged into HIV medical care and treatment services | The number of out-of-care HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic, or unknown, who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care. |
| ME104 | Number of condoms distributed | The total number of condoms distributed. |
| ME105a | Number of condoms distributed to high-risk individuals who are HIV-negative or whose HIV status is unknown | The estimated number of condoms distributed to high-risk HIV-negative individuals and high-risk individuals whose HIV status is unknown. |
| ME105b | Number of condoms distributed to HIV positive individuals | The estimated number of condoms distributed to HIV-positive clients. |
| ME109 | Number of community EBI conducted | The total number of community-level evidence-based interventions (EBI) conducted. A community EBI is defined as an EBI that seeks to improve the risk conditions and behaviors in a community through a focus on the community as a whole. |
| ME110 | Number of people reached by community EBIs | The estimated total number of high-risk HIV-negative individuals that accessed or were reached by (i.e., exposed) community evidence-based interventions (EBIs). A community EBI is defined as an EBI that seeks to improve the risk conditions and behaviors in a community through a focus on the community as a whole. |
| ME111 | Number of social marketing/public information conducted | The total number of social marketing/public information events conducted. Social marketing/public information events are defined as HIV-prevention messages delivered through one or more mass communication channels to target audiences. |
| ME112 | Number of people reached by social marketing/public information events | The estimated total number of people exposed to a key message disseminated by social marketing /public information events. Exposure to a marketing campaign occurs when a person views or hears a key message disseminated by the campaign. |
| ME113 | Number of media placements for marketing campaigns | The total number of media placements for marketing campaigns. A media placement is the use of various types of media to promote or advertise a particular message. HIV/AIDS-related media placements may be produced in a variety of formats. |
| ME114 | Number of clients referred to non-occupational PEP therapy | The number of clients who were referred to non-occupational post-exposure prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114a | Number of MSM/IDU referred to non-occupational PEP therapy | The number of MSM/IDU referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medicallysupervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114b | Number of MSM referred to non-occupational PEP therapy | The number of MSM referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114c | Number of IDU referred to non-occupational PEP therapy | The number of IDU referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114d | Number of high-risk heterosexuals referred to non-occupational PEP therapy | The number of high-risk heterosexuals referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114e | Number of clients with other or unknown risks referred to non-occupational PEP therapy | The number of clients with other behavioral risks (i.e., excluding MSM, IDU, or high-risk heterosexuals) or unknown behavioral risks referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114f | Number of African Americans referred to non-occupational PEP therapy | The number of non-Hispanic blacks or African Americans referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114g | Number of Hispanics referred to non-occupational PEP therapy | The number of Hispanics/Latinos of any race referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME114h | Number of clients of another race/ethnicity referred to non-occupational PEP therapy | The number of clients with a race/ethnicity other than blacks/African Americans or Hispanics, or clients of unknown race/ethnicity referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115 | Number of clients initiated non-occupational PEP therapy | The number of clients who were referred to and initiated non-occupational post-exposure prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115a | Number of MSM/IDU who initiated non-occupational PEP therapy | The number of MSM/IDU who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115b | Number of MSM who initiated non-occupational PEP therapy | The number of MSM who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115c | Number of IDU who initiated non-occupational PEP therapy | The number of IDU who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115d | Number of high-risk heterosexuals who initiated non-occupational PEP therapy | The number of high-risk heterosexuals who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115e | Number of clients with other or unknown risks who initiated non-occupational PEP therapy | The number of clients with other behavioral risks (i.e., excluding MSM, IDU, or high-risk heterosexuals) or unknown behavioral risks who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115f | Number of African American who initiated non-occupational PEP therapy | The number of non-Hispanic blacks or African Americans who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115g | Number of Hispanics who initiated non-occupational PEP therapy | The number of Hispanics/Latinos of any race who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME115h | Number of clients of another race/ethnicity who initiated non-occupational PEP therapy | The number of clients with a race/ethnicity other than blacks/African Americans or Hispanics, or clients of unknown race/ethnicity who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV. |
| ME116 | Number of MSM referred to PrEP therapy | The number of MSM referred to pre-exposure prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME116a | Number of African American MSM referred to PrEP therapy | The number of high-risk non-Hispanic black or African American MSM referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME116b | Number of Hispanic MSM referred to PrEP therapy | The number of Hispanic/Latino MSM of any race referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME116c | Number of MSM of another or unknown race/ethnicity referred to PrEP therapy | The number of MSM clients with a race/ethnicity other than black/African American or Hispanic, or MSM clients of unknown race/ethnicity referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME117 | Number of MSM initiated PrEP therapy | The number of MSM who were referred to and initiated pre-exposure prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME117a | Number of African American MSM who initiated PrEP therapy | The number of non-Hispanic blacks or African Americans MSM who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME117b | Number of Hispanic/Latino MSM who initiated PrEP therapy | The number of Hispanics/Latinos of any race MSM who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME117c | Number of MSM of another or unknown race/ethnicity initiated PrEP therapy | The number of MSM clients with a race/ethnicity other than black/African American or Hispanic, or MSM clients of unknown race/ethnicity who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection. |
| ME203a | Category B total PS12-1201-funded aggregate test events | PS12-1201-funded aggregate test events are test events supported in any way by PS12-1201-funded resources (e.g., funding, test kits, personnel, training and technical assistance, laboratory support), but for which test-level data are not obtainable. |
| ME203b | Category B total reimbursed aggregate test events | Reimbursed aggregate test events are test events that are done in PS12-1201-supported programs, but are actually paid for by a third-party payer (e.g., Medicaid, Medicare, private insurance). |
| ME204a | Category B PS12-1201-funded aggregate newly diagnosed HIV-positive test events | PS12-1201-funded aggregate test events are test events supported in any way by PS12-1201-funded resources (e.g., funding, test kits, personnel, training and technical assistance, laboratory support), but for which test-level data are not obtainable. |
| ME204b | Category B reimbursed aggregate newly diagnosed HIV-positive testing events | Reimbursed aggregate test events are test events that are done in PS12-1201-supported programs, but are actually paid for by a third-party payer (e.g., Medicaid, Medicare, private insurance). |
| ME207a | Number of syphilis tests conducted as part of service integration in healthcare settings | The number of syphilis tests conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME207b | Number of syphilis tests conducted under service integration in non-healthcare settings | The number of syphilis tests conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME208a | Number of gonorrhea tests conducted under service integration in healthcare settings | The number of gonorrhea tests conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME208b | Number of gonorrhea tests conducted under service integration in non-healthcare settings | The number of gonorrhea tests conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME209a | Number of chlamydia tests conducted under service integration in healthcare settings | The number of tests for chlamydial infection conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME209b | Number of chlamydia tests conducted under service integration in non-healthcare settings | The number of tests for chlamydial infection conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME210a | Number of tests for hepatitis B virus conducted under service integration in healthcare settings | The number of tests for hepatitis B virus (HBV) conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME210b | Number of tests for hepatitis B virus conducted under service integration in non-healthcare settings | The number of tests for hepatitis B virus (HBV) conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME211a | Number of tests for hepatitis C virus conducted under service integration in healthcare settings | The number of tests for hepatitis C virus (HCV) conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME211b | Number of tests for hepatitis C virus conducted under service integration in non-healthcare settings | The number of tests for hepatitis C virus (HCV) conducted as part of service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME212a | Number of tuberculosis tests conducted under service integration in healthcare settings | The number of tuberculosis tests conducted as part of service integration for PS 12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME212b | Number of tuberculosis tests conducted under service integration in non-healthcare settings | The number of tuberculosis tests conducted as part of service integration for PS 12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services. |
| ME213a-z | Target population of HIV-positive individuals | Targeted HIV-positive populations (e.g., MSM, IDU, transgender) for prevention interventions. |
| ME214a-z | Total number of HIV-positive persons enrolled in behavioral risk screening | A behavioral risk screen is a brief evaluation of behavioral HIV risk factors used to decide who should be recommended for HIV testing, interventions, or other services. |
| ME215a-z | Total number of HIV-positive persons enrolled in individual- and group-level evidence-based interventions | The total number of HIV-positive persons from the specified Target Population enrolled in individual- and group-level evidence-based interventions. |
| ME216a-z | Total number of HIV-positive persons enrolled in community-level evidence-based interventions | The total number of HIV-positive persons from the specified Target Population enrolled in community-level evidence-based interventions. |
| ME217a-z | Total number of HIV-positive persons enrolled in other locally developed programs | The total number of HIV-positive persons from the specified Target Population enrolled in other locally developed programs. |
| ME218a-z | Target population of high-risk HIV-negative individuals | Targeted high-risk HIV-negative populations for prevention interventions (e.g., MSM, IDU, high-risk heterosexuals, transgender). |
| ME219a-z | Total number of high-risk HIV-negative persons enrolled in behavioral risk screening | A behavioral risk screen is a brief evaluation of behavioral HIV risk factors used to decide who should be recommended for HIV testing, interventions, or other services. |
| ME220a-z | Total number of high-risk HIV-negative persons enrolled in individual- and group-level evidence-based interventions | The total number of high-risk HIV-negative persons from the specified Target Population enrolled in individual- and group-level evidence based interventions. |
| ME221a-z | Total number of high-risk HIV-negative persons enrolled in community-level evidence-based interventions | A community-level evidence-based intervention (EBI) is defined as an EBI that seeks to improve the risk conditions through a focus on the community as a whole, rather than by interviewing only individuals or small groups. |
| ME222a-z | Total number of high-risk HIV-negative persons enrolled in other locally developed programs | The total number of high-risk HIV-negative persons from the specified Target Population enrolled in other locally developed programs. |
|  |  |  |
| CBOCL001 | Date of first visit in this budget year | The date of the client's first visit this budget year |
| CBOCL002 | Budget year | Budget year refers to the PS15-1502 12-month funding period (July 1 - June 30) in which the client received this service. |
| CBOCL005 | Client's HIV Status | The client's self-reported or documented HIV status at the time of his/her first visit this budget year. |
| CBOCL006 | HIV Medical Care | The client's self-report of currently receiving HIV medical care. |
| CBOCL007 | HIV Linked to Medical Care - attended first medical appointment | A client, not currently in HIV medical care, was linked to or re-engaged in HIV medical care - attended first medical appointment. |
| CBOCL008 | Change in HIV Status since the first visit in this budget year | The client's HIV status changed from HIV-negative or unknown to HIV-positive since her/his first visit in this budget year. |
| CBOCL009 | Navigation and prevention and essential support services, RRA | The navigation, prevention, and essential support services that a client was referred to or provided as part of PS15-1502 risk reduction activities. |
| CBOCL009SP | Other recommended support services, RRA | Description of other navigation and prevention and essential support services a client was referred to or provided. |
|  |  |  |